Daré Bioscience to Participate in Upcoming Conferences
Cowen 42nd Annual
March 7-9, 2022, Virtual Sabrina Martucci Johnson, President and Chief Executive Officer, will present live on March 8, 2022at 1:30 p.m. ET.
- Presentation webcast link: https://wsw.com/webcast/cowen108/dare/1986732
Therapeutic Area Partnerships (TAP): Accelerating Innovation in Women’s Health
March 8-9, 2022, Virtual Sabrina Martucci Johnson, President and CEO, will participate in and John Fair, Chief Strategy Officer, will moderate the Solving for “X” panel on March 8, 2022at 11:00 a.m. ET.
- Registration and additional conference details: https://informaconnect.com/therapeutic-area-partnerships-womens-health/
March 13-15, 2022, Laguna Niguel, CA Sabrina Martucci Johnson, President and CEO, will participate in the Emerging Therapies in Women’s Health panel on March 14, 2022at 8:00 a.m. PT. Ms. Johnsonwill also provide a company presentation, available on-demand beginning on March 11, 2022at 5:00 a.m. PT
- Panel webcast link: https://wsw.com/webcast/roth43/panel6/2041752
- Presentation webcast link: https://wsw.com/webcast/roth43/dare/1801712
Archived webcasts will be available under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com as follows:
- Ms. Johnson’s presentation at Cowen’s 42nd Annual
Health Care Conferencewill be available until March 22, 2022.
- The panel discussion and Ms. Johnson’s presentation at the 34th Annual
Roth Conferencewill be available until March 28, 2022.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.
Daré’s first FDA-approved product, XACIATOTM (clindamycin phosphate), is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s product portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about XACIATOTM, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Investors on behalf of Daré
Media on behalf of Daré Bioscience, Inc.:
Source: Daré Bioscience, Inc.